The problem with cancer vaccines isn’t always the vaccine itself—it’s that the immune system doesn’t mount a strong enough T-cell response, and the usual fix, pairing vaccines with cytokine molecules, can make patients dangerously sick. Daniel Anderson’s lab at MIT, working with Harvard and the University of Houston, has now shown a different route: an mRNA-based adjuvant that reprograms immune cells directly, no harsh cytokines required.
This adjuvant consists of mRNA molecules encoding two genes that flip immune cells into a more active state by switching on specific signaling pathways. In mouse models of bladder cancer, colon carcinoma, melanoma, and metastatic lung cancer, lipid nanoparticles carrying this payload slowed tumor growth—and in many cases eradicated tumors entirely. The striking part: this happened even without a vaccine targeting a specific cancer antigen. When researchers did pair the adjuvant with a cancer vaccine, the response got stronger still. The approach also amplified the effects of checkpoint blockade inhibitors, the FDA-approved drugs that lift the brake tumors place on T cells.
Christopher Garris, a Harvard Medical School assistant professor and senior author, framed the finding bluntly: ‘The microenvironment of solid tumors is often hostile to T cells and represents a major barrier to effective immunotherapy. We find that immune remodeling with these adjuvants creates a T-cell-permissive environment and promotes tumor rejection.’
The infectious disease angle is just as compelling. When the mRNA adjuvant was delivered alongside covid or flu vaccines, the T-cell response jumped 10 to 15 times higher than usual. That’s a massive margin—if it translates to humans, it could mean stronger protection for immunocompromised patients or older adults whose vaccine responses typically wane.
Anderson’s group isn’t the only one at MIT pushing adjuvant science forward. Ana Jaklenec’s team at the Koch Institute has used a similar strategy to make the injectable polio vaccine trigger a mucosal immune response in the gut, something previously achievable only with the oral vaccine that many countries abandoned due to rare but real risks. The common thread is clear: mRNA isn’t just for antigens anymore. It’s becoming a tool for rewiring the immune system’s entire posture. The next step is more animal models, but the trajectory here feels less like incremental progress and more like a genuine shift in what vaccines can do.
